Efruxifermin

Efruxifermin is a long-acting FGF-21 analog developed for the treatment of non-alcoholic steatohepatitis (NASH/MASH). It has shown promise in reducing liver fat, inflammation, and fibrosis.

In the literature, Efruxifermin appears most often in work focused on metabolism, inflammation and fat loss. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.

Efruxifermin is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.